Mesoblast Limited (MSB.AX)
AUD 1.7
(5.59%)
AUD 1.7
(5.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 56.36 Million USD | 23.66% |
| 2023 | 45.57 Million USD | -2.77% |
| 2022 | 46.87 Million USD | 249.34% |
| 2021 | -31.38 Million USD | -4.57% |
| 2020 | -30.01 Million USD | -197.26% |
| 2019 | 30.86 Million USD | 42.65% |
| 2018 | 21.63 Million USD | 147.28% |
| 2017 | -45.76 Million USD | -109.34% |
| 2016 | -21.86 Million USD | 20.53% |
| 2015 | -27.5 Million USD | -618.76% |
| 2014 | -3.82 Million USD | 51.4% |
| 2013 | -7.87 Million USD | 96.19% |
| 2012 | -206.74 Million USD | 21.46% |
| 2011 | -263.22 Million USD | -721.32% |
| 2010 | -32.04 Million USD | -93.93% |
| 2009 | -16.52 Million USD | -17.26% |
| 2008 | -14.09 Million USD | -16.92% |
| 2007 | -12.05 Million USD | -53.47% |
| 2006 | -7.85 Million USD | 47.96% |
| 2005 | -15.09 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 41.59 Million USD | -8.74% |
| 2024 FY | 56.36 Million USD | 23.66% |
| 2024 Q4 | 56.36 Million USD | 0.0% |
| 2024 Q2 | 44.85 Million USD | 7.84% |
| 2023 Q2 | 44.56 Million USD | 81.74% |
| 2023 Q4 | 45.57 Million USD | -31.17% |
| 2023 FY | 45.57 Million USD | -2.77% |
| 2023 Q3 | 66.21 Million USD | 48.58% |
| 2023 Q1 | 24.52 Million USD | -47.69% |
| 2022 Q2 | 8.76 Million USD | 200.02% |
| 2022 Q1 | -8.76 Million USD | 72.09% |
| 2022 Q3 | 28.34 Million USD | 223.44% |
| 2022 Q4 | 46.87 Million USD | 65.39% |
| 2022 FY | 46.87 Million USD | 249.34% |
| 2021 Q3 | -55.96 Million USD | -347.04% |
| 2021 FY | -31.38 Million USD | -4.57% |
| 2021 Q1 | -6.67 Million USD | 77.76% |
| 2021 Q2 | 22.65 Million USD | 439.45% |
| 2021 Q4 | -31.38 Million USD | 43.92% |
| 2020 Q1 | 55.04 Million USD | 78.36% |
| 2020 Q2 | 13.37 Million USD | -75.71% |
| 2020 Q3 | 36.06 Million USD | 169.75% |
| 2020 Q4 | -30.01 Million USD | -183.22% |
| 2020 FY | -30.01 Million USD | -197.26% |
| 2019 Q4 | 30.86 Million USD | 220.89% |
| 2019 Q3 | 9.61 Million USD | 173.32% |
| 2019 Q2 | -13.11 Million USD | -300.32% |
| 2019 Q1 | 6.54 Million USD | -69.73% |
| 2019 FY | 30.86 Million USD | 42.65% |
| 2018 Q4 | 21.63 Million USD | 178.5% |
| 2018 FY | 21.63 Million USD | 147.28% |
| 2018 Q3 | -27.55 Million USD | 12.35% |
| 2018 Q2 | -31.44 Million USD | 32.41% |
| 2018 Q1 | -46.51 Million USD | -1.65% |
| 2017 Q1 | -16.03 Million USD | 26.64% |
| 2017 FY | -45.76 Million USD | -109.34% |
| 2017 Q4 | -45.76 Million USD | 7.82% |
| 2017 Q3 | -49.64 Million USD | -189.93% |
| 2017 Q2 | -17.12 Million USD | -6.77% |
| 2016 Q2 | -8.43 Million USD | 89.16% |
| 2016 Q1 | -77.76 Million USD | -182.7% |
| 2016 FY | -21.86 Million USD | 20.53% |
| 2016 Q4 | -21.86 Million USD | -103.12% |
| 2016 Q3 | -10.76 Million USD | -27.63% |
| 2015 Q2 | -11.43 Million USD | 92.33% |
| 2015 Q1 | -149.14 Million USD | -3797.08% |
| 2015 FY | -27.5 Million USD | -618.76% |
| 2015 Q4 | -27.5 Million USD | -122.53% |
| 2015 Q3 | 122.08 Million USD | 1167.84% |
| 2014 Q3 | -182.09 Million USD | -1436.76% |
| 2014 FY | -3.82 Million USD | 51.4% |
| 2014 Q2 | -11.84 Million USD | -103.98% |
| 2014 Q1 | 297.98 Million USD | 3883.89% |
| 2014 Q4 | -3.82 Million USD | 97.9% |
| 2013 Q3 | -328.19 Million USD | -84.14% |
| 2013 FY | -7.87 Million USD | 96.19% |
| 2013 Q4 | -7.87 Million USD | 97.6% |
| 2013 Q1 | -185.37 Million USD | 10.34% |
| 2013 Q2 | -178.23 Million USD | 3.85% |
| 2012 FY | -206.74 Million USD | 21.46% |
| 2012 Q4 | -206.74 Million USD | 0.0% |
| 2011 FY | -263.22 Million USD | -721.32% |
| 2010 FY | -32.04 Million USD | -93.93% |
| 2009 FY | -16.52 Million USD | -17.26% |
| 2008 FY | -14.09 Million USD | -16.92% |
| 2007 FY | -12.05 Million USD | -53.47% |
| 2006 FY | -7.85 Million USD | 47.96% |
| 2005 FY | -15.09 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acrux Limited | -1.45 Million AUD | 3965.569% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | 1946.052% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 141.288% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 130.8% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 429.706% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 403.418% |
| AdAlta Limited | -845.17 Thousand AUD | 6768.457% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 551.608% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 171.065% |
| BTC Health Limited | -2.02 Million AUD | 2887.126% |
| CSL Limited | 15.76 Billion AUD | 99.642% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 398.221% |
| Hexima Limited | -2.22 Million AUD | 2631.652% |
| Immutep Limited | -122.18 Million AUD | 146.125% |
| Memphasys Limited | 4.13 Million AUD | -1262.876% |
| Noxopharm Limited | -2.31 Million AUD | 2529.387% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 654.577% |
| Race Oncology Limited | -17.18 Million AUD | 427.887% |
| Starpharma Holdings Limited | -19.83 Million AUD | 384.187% |
| Tissue Repair Ltd | -16.44 Million AUD | 442.8% |
| Biotron Limited | -386.06 Thousand AUD | 14698.465% |
| Biome Australia Limited | -1.56 Million AUD | 3706.331% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | 5838.682% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | 8042.973% |
| Zelira Therapeutics Limited | 5.06 Million AUD | -1012.223% |
| Patrys Limited | -2.24 Million AUD | 2615.329% |
| Orthocell Limited | -19.92 Million AUD | 382.864% |
| Imugene Limited | -91.56 Million AUD | 161.555% |
| PYC Therapeutics Limited | -65.76 Million AUD | 185.703% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 991.229% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 1008.239% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 543.277% |
| Nanollose Limited | -96.22 Thousand AUD | 58671.057% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 1035.425% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | 1237.634% |
| Amplia Therapeutics Limited | -1.82 Million AUD | 3190.605% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | 4651.001% |
| Nyrada Inc. | -4.76 Million AUD | 1281.706% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 153.274% |
| Dimerix Limited | -21.99 Million AUD | 356.278% |
| PharmAust Limited | -9.71 Million AUD | 680.187% |
| AnteoTech Limited | -5 Million AUD | 1226.857% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 420.564% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | 1759.534% |
| Avecho Biotechnology Limited | -5.32 Million AUD | 1157.561% |
| Actinogen Medical Limited | -9.13 Million AUD | 717.193% |
| Immuron Limited | -11.48 Million AUD | 590.778% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 454.183% |